Surgery of Early-Stage Pancreatic Cancer.
1/5 보강
[BACKGROUND] Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with early detection and surgical resection being the only potentially curative treatment option.
APA
Poppinga J, Ritter AS, et al. (2025). Surgery of Early-Stage Pancreatic Cancer.. Visceral medicine, 41(5), 1-7. https://doi.org/10.1159/000546416
MLA
Poppinga J, et al.. "Surgery of Early-Stage Pancreatic Cancer.." Visceral medicine, vol. 41, no. 5, 2025, pp. 1-7.
PMID
40557115 ↗
Abstract 한글 요약
[BACKGROUND] Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with early detection and surgical resection being the only potentially curative treatment option. Despite advancements in diagnostics and surgical techniques, the prognosis of early-stage PDAC remains poor. Understanding the indications, approaches and perioperative management are crucial for improving patient survival.
[SUMMARY] Surgical resection remains the only curative treatment for early-stage PDAC. Different surgical procedures are performed depending on tumor location and local extent. Advances in minimally invasive surgery (MIS) yielded promising results regarding postoperative recovery and oncologic outcomes. The implementation of neoadjuvant therapy has improved resection and survival rates. Still, pancreatic surgery is associated with significant morbidity.
[KEY MESSAGES] Surgical resection remains the only curative option for early-stage pancreatic cancer. Neoadjuvant chemotherapy plays a crucial role in improving resection and survival rates. Perioperative care has been refined by MIS, optimized surgical techniques, and structured complication management.
[SUMMARY] Surgical resection remains the only curative treatment for early-stage PDAC. Different surgical procedures are performed depending on tumor location and local extent. Advances in minimally invasive surgery (MIS) yielded promising results regarding postoperative recovery and oncologic outcomes. The implementation of neoadjuvant therapy has improved resection and survival rates. Still, pancreatic surgery is associated with significant morbidity.
[KEY MESSAGES] Surgical resection remains the only curative option for early-stage pancreatic cancer. Neoadjuvant chemotherapy plays a crucial role in improving resection and survival rates. Perioperative care has been refined by MIS, optimized surgical techniques, and structured complication management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- Racial Disparities in Pancreatic Cancer: A Comprehensive Population-Based Analysis of Survival, Surgical Access, and Prognostic Factors.
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.